Blog
RSS FeedPosted by Michael Wonder on 17 Apr 2020
Bayer donates 8 million chloroquine tablets to the German Federal Government
14 April 2020 - Additional donations of chloroquine sent to governments in numerous other countries. ...
Posted by Michael Wonder on 23 Mar 2020
Determinants of orphan drug prices in Germany
21 March 2020 - Legislation introduced in 2011 in Germany has instituted an early benefit assessment of newly licensed pharmaceuticals with ...
Posted by Michael Wonder on 25 Jan 2020
Registry-data – of sufficient quality – are suitable for the extended benefit assessment of drugs
24 January 2020 - Rapid report shows how routine practice data should be collected and processed. ...
Posted by Michael Wonder on 16 Jan 2020
Asfotase alfa in hypophosphatasia in children and adolescents: survival advantage for small children
15 January 2020 - Weak evidence does not allow a specific statement to be made about the extent of the added ...
Posted by Michael Wonder on 16 Jan 2020
Larotrectinib in tumours with NTRK gene fusion: data are not yet sufficient for derivation of an added benefit
15 January 2020 - First assessment of a histology-independent drug/studies without control arms. ...
Posted by Michael Wonder on 23 Sep 2019
Pembrolizumab in metastatic NSCLC: now added benefit for subpopulations
19 September 2019 - After a methodological uncertainty has been resolved, analyses on overall survival are now usable ...
Posted by Michael Wonder on 11 Sep 2019
Germany may have the answer for reducing drug prices
11 September 2019 - American lawmakers attempting to stem spiraling drug costs might find inspiration in Germany, where the government’s ...
Posted by Michael Wonder on 05 Aug 2019
Dacomitinib in advanced lung cancer: variety of disadvantages lifts survival advantage
1 August 2019 - Prolonged survival is sometimes accompanied by severe side effects, symptom and quality of life deterioration ...
Posted by Michael Wonder on 31 Jul 2019
Ezetimibe reduces the risk of heart attacks and strokes
26 July 2019 - Added to existing statin therapy, ezetimibe is preventative in patients with CHD and acute coronary syndrome. ...
Posted by Michael Wonder on 13 Jul 2019
Early benefit assessment reveals weaknesses in the development of new drugs
11 July 2019 - Analysis of 216 AMNOG assessments in the BMJ / Proposals for more targeted drug development ...
Posted by Michael Wonder on 11 Jul 2019
New drugs: where did we go wrong and what can we do better?
10 July 2019 - More than half of new drugs entering the German health care system have not been shown to ...
Posted by Michael Wonder on 10 Jul 2019
Biomarker-based cancer diagnostics: German pricing regulator sets high validation and reimbursement standards for novel diagnostic methods
10 July 2019 - On 20 June 2019, for the first time, the German Federal Joint Committee (G-BA), made the resolution ...
Posted by Michael Wonder on 08 Jun 2019
UK, Germany, dissociate from WHO drug pricing resolution
8 June 2019 - The passage of a landmark resolution on improving the transparency of markets for medicines at the latest ...
Posted by Michael Wonder on 15 May 2019
Nivolumab and ipilimumab: drug combination has added benefit in advanced renal cell carcinoma
15 May 2019 - There are no serious disadvantages in terms of overall survival. ...
Posted by Michael Wonder on 02 May 2019
Apalutamide in prostate cancer: indication of significant added benefit
2 May 2019 - Study shows significant slowing of symptomatic progression. ...